Otsuka, in collaboration with the Center for Myeloid Blood Cancer (CMYC) in Bergen, arranges an AML webinar with the purpose to increase the knowledge of current less intensive AML therapies.

Read more and register here: AML webinar with A Isidori

Agenda

 x Welcome and product information, by Ivar Haukeland, BM, Otsuka Pharma Scandinavia AB

 x A short introduction to the landscape of less intensive treatment for eldery AML-patients, by Prof, MD, PhD Bjørn Tore Gjertsen

 x Clinical management of elderly patients with AML not eligible for intensive chemotherapy: an overview, by Alessandro Isidori, MD, PhD

 x Questions and discussion, lead by Prof, MD, PhD Bjørn Tore Gjertsen